In lung cancer patients, for example, tumors with EGFR mutations have a higher rate of mutant TP53. Moreover, the presence of these p53 mutations is a negative prognostic factor [19] and is even associated with a lower response to EGFR inhibitors in lung tumors [20]. This evidence concerns the gene EGFR and lung cancer.